The global biotechnology market is expected to undergo a number of transformations. These include a shift of growth from the developed to the emerging markets, an increasing focus on monoclonal antibodies and an increasing penetration of biosimilars/follow-on-biologics.

1. Global Biotechnology Market Expected to Undergo a Number of
Transformations
The global biotechnology market is expected to undergo a number of transformations. These
include a shift of growth from the developed to the emerging markets, an increasing focus on
monoclonal antibodies and an increasing penetration of biosimilars/follow-on-biologics.
The global biotechnology market is expected to grow at a CAGR of 7% during 2013-2017
reaching sales worth nearly US$ 166 billion by 2017. This market, however, is expected to
undergo a number of transformations which would impact the course of its growth. These
transitions include a shift of growth from the developed to the emerging markets, an
increasing focus on monoclonal antibodies compared to therapeutic proteins and an
increasing penetration of biosimilars/follow-on-biologics compared to their branded versions.
As a result of these transformations, the need for a user friendly, robust and comprehensive
biotechnology market intelligence has become imperative for investors, researchers,
consultants, marketing strategists, and all those who are planning to foray into the
biotechnology market in some form or the other.
IMARC Group, one of the world’s leading research and advisory firms, introduces a new and
revolutionary way to understand and evaluate the global biotechnology market with its new
report entitled “Global Biopharmaceutical Market Report & Forecast: 2012-2017”. This
report provides an analytical and statistical insight into the global biotechnology market. The
study, which has been undertaken using desk based as well as primary market research is a
must for: pharmaceutical manufacturers, biopharmaceutical manufacturers, drug delivery
device manufacturers, PE firms, FDI investors, planning agencies, consultants, research
firms, credit rating agencies, etc.
Regions/Countries Covered:
North America: United States and Canada
Latin America: Mexico, Brazil and Argentina
Europe: Germany, France, Italy, Spain, United Kingdom, Russia and Turkey
Asia Pacific: Japan, China, Australia, South Korea, India and Indonesia
Table of Contents
1. Market Definitions & Research Methodology
2. Analyst Briefing

2. 3. Introduction to Biopharmaceuticals
4. Global Biopharmaceutical Market: Industry Analysis
4.1 Strengths
4.1.1 High Efficacy and Target Oriented Attack
4.1.2 Strong Potential to Achieve Blockbuster Status
4.1.3 Limited Generic Threat
4.1.4 Approval Success Rates are Higher than Small Molecule Drugs
4.2 Weaknesses
4.2.1 Inconvenient Drug Delivery Coupled with Short Half Lives
4.2.2 Second Line of Therapy
4.2.3 Huge Cost of Therapy
4.2.4 High Incidence of Unfavorable Side Effects
4.3 Opportunities
4.3.1 Diseases with High Unmet Needs
4.3.2 Expanding the Patient Pool by Approval into Additional Indications
4.3.3 Emerging Markets
4.3.4 Increasing New Approvals and a Strong Pipeline
4.4 Threats
4.4.1 Biopharmaceutical Drug Development is a Very Risky Venture
4.4.2 Biosimilars
4.4.3 Limited and Conditional Reimbursement
4.4.4 Uncertainties in the Economic Environment
5. Global Biopharmaceutical Market: Industry Performance
5.1 Market Performance & Forecast
5.1.1 Current Performance (2005-2011)
5.1.2 Market Forecast (2012-2017)
5.2 Market Segmentation by Region
5.2.1 Current Performance (2005-2011)
5.2.2 Market Forecast (2012-2017)
5.3 Market Segmentation by Indication
5.4 Market Segmentation by Class
5.4.1 Recombinant Proteins
5.4.1.1 Current Performance (2005-2011)
5.4.1.2 Market Forecast (2012-2017)
5.4.2 Monoclonal Antibodies
5.4.2.1 Current Performance (2005-2011)
5.4.2.2 Market Forecast (2012-2017)

3. 5.4.3 Purified Proteins
5.4.3.1 Current Performance (2005-2011)
5.4.3.2 Market Forecast (2012-2017)
5.5 Competitive Landscape
5.5.1 Top Biopharmaceutical Players
5.5.2 Top Biopharmaceutical Drugs
6. North America
6.1 US
6.1.1 Market Performance (2005-2011)
6.1.2 Market Segmentation by Class
6.1.2.1 Recombinant Proteins
6.1.2.2 Monoclonal Antibodies
6.1.2.3 Purified Proteins
6.1.3 Performance of Top Players
6.1.4 Market Forecast (2012-2017)
6.2 Canada
6.2.1 Market Performance (2005-2011)
6.2.2 Market Segmentation by Class
6.2.2.1 Recombinant Proteins
6.2.2.2 Monoclonal Antibodies
6.2.3 Performance of Top Players
6.2.4 Market Forecast (2012-2017)
7. Latin America
7.1 Mexico
7.1.1 Market Performance (2005-2011)
7.1.2 Market Segmentation by Class
7.1.2.1 Recombinant Proteins
7.1.2.2 Monoclonal Antibodies
7.1.2.3 Purified Proteins
7.1.3 Performance of Top Players
7.1.4 Market Forecast (2012-2017)
7.2 Brazil
7.2.1 Market Performance (2005-2011)
7.2.2 Market Segmentation by Class
7.2.2.1 Recombinant Proteins
7.2.2.2 Monoclonal Antibodies
7.2.2.3 Purified Proteins

4. 7.2.3 Performance of Top Players
7.2.4 Market Forecast (2012-2017)
7.3 Argentina
7.3.1 Market Performance (2005-2011)
7.3.2 Market Segmentation by Class
7.3.2.1 Recombinant Proteins
7.3.2.2 Monoclonal Antibodies
7.3.2.3 Purified Proteins
7.3.3 Performance of Top Players
7.3.4 Market Forecast (2012-2017)
8. Europe
8.1 Germany
8.1.1 Market Performance (2005-2011)
8.1.2 Market Segmentation by Class
8.1.2.1 Recombinant Proteins
8.1.2.2 Monoclonal Antibodies
8.1.2.3 Purified Proteins
8.1.3 Performance of Top Players
8.1.4 Market Forecast (2012-2017)
8.2 France
8.2.1 Market Performance (2005-2011)
8.2.2 Market Segmentation by Class
8.2.2.1 Recombinant Proteins
8.2.2.2 Monoclonal Antibodies
8.2.2.3 Purified Proteins
8.2.3 Performance of Top Players
8.2.4 Market Forecast (2012-2017)
8.3 Italy
8.3.1 Market Performance (2005-2011)
8.3.2 Market Segmentation by Class
8.3.2.1 Recombinant Proteins
8.3.2.2 Monoclonal Antibodies
8.3.2.3 Purified Proteins
8.3.3 Performance of Top Players
8.3.4 Market Forecast (2012-2017)
8.4 Spain
8.4.1 Market Performance (2005-2011)

5. 8.4.2 Market Segmentation by Class
8.4.2.1 Recombinant Proteins
8.4.2.2 Monoclonal Antibodies
8.4.2.3 Purified Proteins
8.4.3 Performance of Top Players
8.4.4 Market Forecast (2012-2017)
8.5 UK
8.5.1 Market Performance (2005-2011)
8.5.2 Market Segmentation by Class
8.5.2.1 Recombinant Proteins
8.5.2.2 Monoclonal Antibodies
8.5.2.3 Purified Proteins
8.5.3 Performance of Top Players
8.5.4 Market Forecast (2012-2017)
8.6 Russia
8.6.1 Market Performance (2005-2011)
8.6.2 Market Segmentation by Class
8.6.2.1 Recombinant Proteins
8.6.2.2 Monoclonal Antibodies
8.6.2.3 Purified Proteins
8.6.3 Performance of Top Players
8.6.4 Market Forecast (2012-2017)
8.7 Turkey
8.7.1 Market Performance (2005-2011)
8.7.2 Market Segmentation by Class
8.7.2.1 Recombinant Proteins
8.7.2.2 Monoclonal Antibodies
8.7.2.3 Purified Proteins
8.7.3 Performance of Top Players
8.7.4 Market Forecast (2012-2017)
9. Asia Pacific
9.1 Japan
9.1.1 Market Performance (2005-2011)
9.1.2 Market Segmentation by Class
9.1.2.1 Recombinant Proteins
9.1.2.2 Monoclonal Antibodies
9.1.2.3 Purified Proteins

6. 9.1.3 Performance of Top Players
9.1.4 Market Forecast (2012-2017)
9.2 China
9.2.1 Market Performance (2005-2011)
9.2.2 Market Segmentation by Class
9.2.2.1 Recombinant Proteins
9.2.2.2 Monoclonal Antibodies
9.2.2.3 Purified Proteins
9.2.3 Performance of Top Players
9.2.4 Market Forecast (2012-2017)
9.3 Australia
9.3.1 Market Performance (2005-2011)
9.3.2 Market Segmentation by Class
9.3.2.1 Recombinant Proteins
9.3.2.2 Monoclonal Antibodies
9.3.2.3 Purified Proteins
9.3.3 Performance of Top Players
9.3.4 Market Forecast (2012-2017)
9.4 South Korea
9.4.1 Market Performance (2005-2011)
9.4.2 Market Segmentation by Class
9.4.2.1 Recombinant Proteins
9.4.2.2 Monoclonal Antibodies
9.4.2.3 Purified Proteins
9.4.3 Performance of Top Players
9.4.4 Market Forecast (2012-2017)
9.5 India
9.5.1 Market Performance (2005-2011)
9.5.2 Market Segmentation by Class
9.5.2.1 Recombinant Proteins
9.5.2.2 Monoclonal Antibodies
9.5.2.3 Purified Proteins
9.5.3 Performance of Top Players
9.5.4 Market Forecast (2012-2017)
9.6 Indonesia
9.6.1 Market Performance (2005-2011)
9.6.2 Market Segmentation by Class

7. 9.6.2.1 Recombinant Proteins
9.6.2.2 Monoclonal Antibodies
9.6.3 Performance of Top Players
9.6.4 Market Forecast (2012-2017)
To buy the complete report or to get a free sample, please contact:
IMARC Group Asia
Email: apac@imarcgroup.com
Phone: +91-120-415-5099
IMARC Group North America
Email: america@imarcgroup.com
Phone: +1-631-791-1145
IMARC Group Europe, Middle East & Africa
Email:ema@imarcgroup.com
Phone: +44-702-409-7331
To know more please visit: http://www.imarcgroup.com/global-biopharmaceutica-market-
report-forecasts-2012-2017/